Does Insurance Cover Peptide Therapy?

• Insurance covers a diagnosis rather than a peptide. An FDA-approved peptide prescribed for an approved condition may be covered, and the same drug for another reason usually isn't.
• Wellness and compounded peptides are self-pay. BPC-157, TB-500, and other unapproved peptides aren't covered by any plan.
• Medicare now has a $50 GLP-1 option. The Medicare GLP-1 Bridge covers Wegovy and Zepbound for eligible people from July 1, 2026, through December 31, 2027.
• Oregon state employees on PEBB don't have GLP-1 weight loss coverage in 2026. The board said it would review options for 2027.
• HSA and FSA funds can often help. The IRS allows weight-loss treatment for a diagnosed disease like obesity, along with prescribed drugs.

• Will insurance pay for peptide therapy?
• Peptide coverage at a glance
• When insurance covers peptides
• When insurance won't cover peptides
• Does Medicare cover GLP-1 peptides in 2026?
• Coverage in Oregon
• Can you use HSA or FSA funds for peptide therapy?
• How to get peptides covered by insurance
• What peptide therapy costs without insurance
• Common myths about peptide coverage
• What-if scenarios
• Frequently asked questions
• What to do next

Insurance pays for peptide therapy when the peptide is FDA-approved and prescribed for a condition your plan covers, and it doesn't pay for wellness, anti-aging, or recovery peptides.

That's the short version.

Insurers cover a specific drug for a specific diagnosis rather than "peptide therapy" as a category. Semaglutide is a peptide, and as Ozempic for type 2 diabetes, it's commonly covered. The same molecule as Wegovy for weight loss may or may not be covered, which is one of the real differences between Wegovy and Ozempic. And a peptide like BPC-157 for a sore shoulder isn't covered at all, since it isn't FDA-approved for anything.

So the real question to ask is, "Is my drug approved for my diagnosis, and does my plan cover that use?"

This table shows how likely coverage is for common peptides, based on FDA status and the reason they're prescribed.

Here's what most people miss. The same active ingredient can land in three different rows depending on the brand, the diagnosis, and who's paying.

Insurance covers peptides when there's an FDA-approved drug, a covered diagnosis, and paperwork showing you meet your plan's criteria.

Those three pieces usually look like this:

• An FDA-approved, brand-name drug. Insurers cover approved products from licensed pharmacies.
• A qualifying diagnosis. Type 2 diabetes, obesity with a BMI over your plan's cutoff, or heart disease with obesity are common examples.
• Prior authorization. Your provider sends your records, BMI, lab results, and sometimes proof that you tried other approaches first.

Diabetes coverage is the most reliable. For weight loss, coverage depends heavily on your employer. In 2025, 19% of large employers covered GLP-1 drugs for weight loss, and that rose to 43% among companies with 5,000 or more workers.

So if you work for a large company, check your plan first. You may have coverage you didn't know about.

Insurance won't cover peptides that aren't FDA-approved, compounded versions of approved drugs, or any peptide prescribed for wellness, anti-aging, or performance.

Unapproved peptides like BPC-157, TB-500, MOTS-c, and Semax are the clearest example. FDA hasn't approved them for any use, and even after a July 2026 advisory vote, their compounding status is still pending. The human evidence for these peptides is still thin, which is another reason insurers won't pay for them.

Compounded versions of approved drugs aren't covered either. A compounded semaglutide isn't the same product as Wegovy in an insurer's eyes, so it's self-pay even when you'd qualify for the brand-name drug.

Wellness goals are excluded too. Plans exclude treatments meant for general health, energy, or appearance, even when a licensed provider prescribes them.

Yes, Medicare covers Wegovy and Zepbound for weight loss through the Medicare GLP-1 Bridge, at $50 a month for eligible people from July 1, 2026, through December 31, 2027.

This is a big change. Medicare Part D has excluded drugs used for weight loss since the program started in 2006. In March 2024, Wegovy became coverable under Part D for one specific use, lowering the risk of heart attack and stroke in adults with heart disease and obesity.

The Medicare GLP-1 Bridge goes further. Here's how it works:

• Cost: $50 for each one-month supply, which doesn't count toward your Part D deductible or yearly out-of-pocket limit.
• Drugs: Wegovy (injection or tablet), Zepbound (KwikPen only), and Foundayo tablets.
• Who qualifies: Adults with a BMI of 35 or higher; a BMI of 30 to 34.9 with conditions like heart failure, high blood pressure, or kidney disease; or a BMI of 27 to 29.9 with prediabetes, a prior heart attack or stroke, or peripheral artery disease.
• Who doesn't: People already getting a GLP-1 through Part D, and people with type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease.
• How to start: Your provider submits a prior authorization, including confirmation that you've received lifestyle counseling.

Let's do the math together. At $50 a month, a year on the Bridge costs $600. The same Wegovy at the manufacturer's $349 self-pay price costs about $4,188. If you're on Medicare and qualify, that's a difference of roughly $3,588 a year.

In Oregon, coverage depends on whether you have Medicare, a state employee plan, the Oregon Health Plan, or a private or employer plan.

• Medicare (including Medicare Advantage): The $50 GLP-1 Bridge applies in Oregon like everywhere else.
• PEBB (state employees): PEBB plans don't cover GLP-1s for weight loss in 2026, with rare exceptions, and the board said it would review options for 2027. Diabetes coverage is separate.
• Oregon Health Plan: Coverage rules for weight loss drugs can change, so ask your coordinated care organization what's covered for your diagnosis.
• Employer and individual plans: These vary plan by plan. Call the number on your card and ask about your specific drug and diagnosis.

If you live in Salem and work for the state, a hospital, or a school district, your plan's rules may differ from a neighbor's on the same street. That's normal, and it's why the phone call to your insurer matters.

You can often use HSA or FSA funds for prescribed peptides that treat a diagnosed condition, and you usually can't for wellness or general health.

IRS Publication 502 sets the rules. Medical expenses have to be primarily for preventing or treating an illness, and expenses that are only good for general health don't count. Weight-loss treatment counts when it treats a specific disease diagnosed by a physician, such as obesity, high blood pressure, or heart disease. Prescribed drugs count too.

In practice, that means:

• A GLP-1 prescribed for diagnosed obesity or diabetes is generally an eligible expense.
• Medical visits and labs for that treatment are generally eligible.
• Peptides for anti-aging or general wellness are generally not eligible.

Your HSA or FSA administrator makes the final call, and some ask for a letter of medical necessity. Keep your receipts and the diagnosis on file.

To get peptides covered, confirm your plan covers the drug for your diagnosis, then have your provider submit a complete prior authorization.

• Call your insurer. Ask, "Is [drug name] covered for [diagnosis] on my plan, and does it need prior authorization?"
• Ask about the criteria. Many plans require a certain BMI, a related health condition, or proof that you tried diet and exercise first.
• Get your records ready. Recent weight, BMI, labs, and notes about past weight loss attempts help.
• Have your provider submit the prior authorization. Missing details are a common reason for denials, and a provider who handles getting semaglutide regularly knows what insurers ask for.
• Appeal if denied. Denials can be appealed, and a letter from your provider explaining medical necessity helps.

If your plan simply excludes weight loss drugs, an appeal is unlikely to change that. That's when self-pay options and HSA or FSA funds come in.

Without insurance, brand-name GLP-1s cost about $149 to $399 a month through manufacturer self-pay programs, and wellness peptides typically cost $150 to $400 a month.

Wegovy's self-pay prices currently run $349 a month for most injection doses, with a new-patient offer of $199 a month for the first two fills of the lowest doses through December 31, 2026. Wegovy tablets start at $149 a month.

Supervised programs add labs and follow-up visits on top of the drug, and typical peptide therapy costs reflect that. For GLP-1 injections in Salem, the full price depends on your plan, and we go over it at your free consultation.

Red flags:

• A clinic promising your insurance will cover an unapproved peptide.
• A provider coding a wellness peptide under a different diagnosis to get it paid. That's insurance fraud, and you could be responsible for the bill.
• Online sellers offering "insurance-free" peptides with no prescription or medical visit.

• "If a provider prescribes it, insurance has to cover it." Coverage depends on FDA approval, your diagnosis, and your plan's rules.
• "Compounded semaglutide is covered like Wegovy." Compounded versions aren't FDA-approved products, so plans don't cover them.
• "Medicare never covers weight loss drugs." That changed with the Medicare GLP-1 Bridge, which started July 1, 2026.
• "HSA money can pay for anything a clinic sells." The IRS limits HSA and FSA spending to treating or preventing illness, so wellness peptides usually don't qualify.

What if your insurance denied your GLP-1? Ask why in writing. If it's missing information, your provider can resubmit. If your plan excludes weight loss drugs, ask whether you qualify under another diagnosis, like diabetes or heart disease, that the plan does cover.

What if you're turning 65 soon? Once you're on a Medicare Part D or Medicare Advantage plan, you can ask your provider whether you qualify for the $50 Bridge.

What if you want a recovery peptide for an injury? Insurance won't cover it. Physical therapy and imaging are often covered, and they have far stronger evidence.

What if your coverage ends mid-treatment? Talk to your provider about switching to a self-pay program, since stopping semaglutide can mean regaining weight, and managing a GLP-1 on your own carries its own risks.